Meyahealth
HomeGeneticsGeneMSTN gene
Back to Gene
MSTN gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

MSTN gene

The MSTN gene provides instructions for making myostatin, a protein that acts as a critical regulator to limit muscle growth in the body.

Normal Function

The MSTN gene provides instructions for making a protein called myostatin. This protein is part of the transforming growth factor beta (TGFβ) superfamily, which is a group of proteins that help control the growth and development of tissues throughout the body. Myostatin is found almost exclusively in muscles used for movement (skeletal muscles), where it is active both before and after birth. This protein normally limits muscle growth, ensuring that muscles do not grow too large.

Researchers are studying myostatin as a potential treatment for various muscular dystrophies that cause muscle weakness and wasting (atrophy).

Health Conditions Related to Genetic Changes

Myostatin-related muscle hypertrophy

At least one variant in the MSTN gene has been found to cause myostatin-related muscle hypertrophy, a rare condition characterized by increased muscle mass and strength. The variant, which is written as IVS1+5G>A, disrupts the way the gene's instructions are used to make myostatin. As a result, cells produce little or no functional myostatin. A loss of this protein in muscle cells leads to an overgrowth of muscle tissue. It does not appear to cause any other medical problems in affected individuals.

Other Names for This Gene

  • GDF-8
  • GDF8
  • GDF8_HUMAN
  • growth differentiation factor 8

Frequently Asked Questions

variant that lowers myostatin levels can lead to increased muscle mass and strength, a condition known as myostatin-related muscle hypertrophy. Individuals with this variant typically have larger muscles but usually do not experience other health problems. However, they may be at higher risk for musculoskeletal strain, so regular strength training and proper warm‑up are advised.
Using myostatin inhibitors is not recommended for athletes because these drugs are experimental, not approved for performance enhancement, and can carry unknown side effects. Athletes should rely on proven training, nutrition, and recovery protocols instead.
Yes, a targeted genetic test for known MSTN variants (such as IVS1+5G>A) can confirm the presence of a myostatin‑deficiency mutation. A qualified genetic counselor can interpret the results and discuss implications for family members.
Research is ongoing to use myostatin inhibitors to increase muscle mass in muscular dystrophy patients. Early trials show promise, but safety and long‑term efficacy are still being evaluated. Patients should discuss participation in clinical trials with their neurologist or geneticist.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ